Prognostic and Clinicopathological Value of Rac1 in Cancer Survival: Evidence from a Meta-Analysis

Lou, Shu; Wang, Penglai; Yang, Jianrong; Ma, Junqing; Liu, Chao; Zhou, Meng

doi:10.7150/jca.24824



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2018; 9(14):2571-2579. doi:10.7150/jca.24824 This issue Cite

Review

Prognostic and Clinicopathological Value of Rac1 in Cancer Survival: Evidence from a Meta-Analysis

Shu Lou^2*, Penglai Wang^1*, Jianrong Yang², Junqing Ma², Chao Liu^1✉, Meng Zhou^1,2✉

1. Department of oral and maxillofacial surgery, Xuzhou Stomatological Hospital, 130 Huaihai Road, Xuzhou, Jiangsu 221002, China
2. Jiangsu Key Laboratory of Oral Diseases, Nanjing Medical University, 136 Hanzhong Road, Nanjing, Jiangsu 210029, China
*Shu Lou and Penglai Wang have contributed equally to this work.

Citation:

Lou S, Wang P, Yang J, Ma J, Liu C, Zhou M. Prognostic and Clinicopathological Value of Rac1 in Cancer Survival: Evidence from a Meta-Analysis. J Cancer 2018; 9(14):2571-2579. doi:10.7150/jca.24824. https://www.jcancer.org/v09p2571.htm

Other styles

Abstract

Purpose: The role of Rac1 in cancer survival has been widely studied. However, the prognostic and clinicopathological value of Rac1 remains inconclusive. We performed a meta-analysis to clarify the role of Rac1 in cancer survival as well as its association with clinicopathological features.

Methods: Eligible studies were searched from PubMed, Cochrane Library, Embase, and Web of Science databases. The pooled hazard ratios (HRs) and odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were used to detect the prognostic and clinicopathological role of Rac1.

Results: A total of 14 studies including 1793 patients were enrolled in the present meta-analysis. Pooled HR for overall survival (OS) (HR=2.02, 95% CI: 1.70-2.39) and disease-free survival (DFS) (HR=2.64, 95% CI: 1.71-4.09) indicated a significant poor prognostic effect for Rac1. Positive Rac1 expression was found to be correlated with tumor stage, blood vessel invasion, and lymph metastasis, but not with histological differentiation. Sensitivity test showed no single study altered OS or DFS significantly. No publication bias was detected by Egger's test and Begg's funnel plot test.

Conclusion: This meta-analysis indicated that Rac1 could be used as a potential marker to predict cancer prognosis. Additionally, Rac1 expression was associated with the malignancy-related phenotype.

Keywords: Rac1, cancer, prognosis, biomarker, Meta-analysis

Citation styles

APA

Lou, S., Wang, P., Yang, J., Ma, J., Liu, C., Zhou, M. (2018). Prognostic and Clinicopathological Value of Rac1 in Cancer Survival: Evidence from a Meta-Analysis. Journal of Cancer, 9(14), 2571-2579. https://doi.org/10.7150/jca.24824.

ACS

Lou, S.; Wang, P.; Yang, J.; Ma, J.; Liu, C.; Zhou, M. Prognostic and Clinicopathological Value of Rac1 in Cancer Survival: Evidence from a Meta-Analysis. J. Cancer 2018, 9 (14), 2571-2579. DOI: 10.7150/jca.24824.

NLM

CSE

Lou S, Wang P, Yang J, Ma J, Liu C, Zhou M. 2018. Prognostic and Clinicopathological Value of Rac1 in Cancer Survival: Evidence from a Meta-Analysis. J Cancer. 9(14):2571-2579.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.